Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib.
Ooi MG, Hayden PJ, Kotoula V, McMillin DW, Charalambous E, Daskalaki E, Raje NS, Munshi NC, Chauhan D, Hideshima T, Buon L, Clynes M, O'Gorman P, Richardson PG, Mitsiades CS, Anderson KC, Mitsiades N. Ooi MG, et al. Among authors: charalambous e. Clin Cancer Res. 2009 Dec 1;15(23):7153-60. doi: 10.1158/1078-0432.CCR-09-1071. Epub 2009 Nov 24. Clin Cancer Res. 2009. PMID: 19934289 Free PMC article.
Association of VEGF-A splice variant mRNA expression with outcome in bevacizumab-treated patients with metastatic breast cancer.
Pentheroudakis G, Kotoula V, Kouvatseas G, Charalambous E, Dionysopoulos D, Zagouri F, Koutras A, Papazisis K, Pectasides D, Samantas E, Dimopoulos MA, Papandreou CN, Fountzilas G. Pentheroudakis G, et al. Among authors: charalambous e. Clin Breast Cancer. 2014 Oct;14(5):330-8. doi: 10.1016/j.clbc.2014.02.009. Epub 2014 Mar 1. Clin Breast Cancer. 2014. PMID: 24703319 Clinical Trial.
Mutational profiling of the RAS, PI3K, MET and b-catenin pathways in cancer of unknown primary: a retrospective study of the Hellenic Cooperative Oncology Group.
Pentheroudakis G, Kotteas EA, Kotoula V, Papadopoulou K, Charalambous E, Cervantes A, Ciuleanu T, Fountzilas G, Pavlidis N. Pentheroudakis G, et al. Among authors: charalambous e. Clin Exp Metastasis. 2014 Oct;31(7):761-9. doi: 10.1007/s10585-014-9666-1. Epub 2014 Jul 5. Clin Exp Metastasis. 2014. PMID: 24997156
A study of gene expression markers for predictive significance for bevacizumab benefit in patients with metastatic colon cancer: a translational research study of the Hellenic Cooperative Oncology Group (HeCOG).
Pentheroudakis G, Kotoula V, Fountzilas E, Kouvatseas G, Basdanis G, Xanthakis I, Makatsoris T, Charalambous E, Papamichael D, Samantas E, Papakostas P, Bafaloukos D, Razis E, Christodoulou C, Varthalitis I, Pavlidis N, Fountzilas G. Pentheroudakis G, et al. Among authors: charalambous e. BMC Cancer. 2014 Feb 20;14:111. doi: 10.1186/1471-2407-14-111. BMC Cancer. 2014. PMID: 24555920 Free PMC article.
MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer.
Gogas H, Kotoula V, Alexopoulou Z, Christodoulou C, Kostopoulos I, Bobos M, Raptou G, Charalambous E, Tsolaki E, Xanthakis I, Pentheroudakis G, Koutras A, Bafaloukos D, Papakostas P, Aravantinos G, Psyrri A, Petraki K, Kalogeras KT, Pectasides D, Fountzilas G. Gogas H, et al. Among authors: charalambous e. J Transl Med. 2016 May 17;14(1):136. doi: 10.1186/s12967-016-0883-z. J Transl Med. 2016. PMID: 27184134 Free PMC article.
The CpG island methylator phenotype is concordant between primary colorectal carcinoma and matched distant metastases.
Cohen SA, Yu M, Baker K, Redman M, Wu C, Heinzerling TJ, Wirtz RM, Charalambous E, Pentheroudakis G, Kotoula V, Kalogeras KT, Fountzilas G, Grady WM. Cohen SA, et al. Among authors: charalambous e. Clin Epigenetics. 2017 May 2;9:46. doi: 10.1186/s13148-017-0347-1. eCollection 2017. Clin Epigenetics. 2017. PMID: 28469732 Free PMC article.
37 results